Japanese Encephalitis Therapeutics Pipeline Analysis, 2017

Japanese Encephalitis Therapeutics Pipeline Analysis, 2017

  • October 2017 •
  • 60 pages •
  • Report ID: 5245000
Japanese encephalitis therapeutics pipeline in 2017

Japanese encephalitis is a viral infection that spreads by mosquito bites. The study analyzed that the Japanese encephalitis therapeutics pipeline comprises approximately 12 drug candidates in different stages of development.

Insights on pipeline segments
Shandong Hengye Biotech Co., Ltd., and VABIOTECH, have one drug candidates each in the Phase III stage of development for the treatment of the disease. The clinical studies of the vaccine, Vero cell-derived inactivated, is currently going on in China in the Phase III stage of development for the treatment of Japanese encephalitis.

Maximum drugs being developed as vaccines
The companies developing drugs for the treatment of Japanese encephalitis are laying more emphasis on the drug candidates to be developed as vaccines, due to the promising results shown by these candidates the in the clinical development. Based on molecule type, around 75.0% of the therapeutic candidates are being developed as vaccines, around 13.0% are made as peptide and 12.0% are being developed as small molecule.

Various collaborations for Japanese Encephalitis drug development
In September 2017, VABIOTECH in collaboration with National Institute of Hygiene and Epidemiology (NIHE), Vietnam, initiated a Phase III, randomized, multi-centered, parallel groups assignment trial to assess the immunogenicity and safety of the JECEVAX in healthy male as well as female children of age between nine to 24 months.

Some of the key players developing drugs for the treatment of Japanese encephalitis include Shandong Hengye Biotech, Co. Ltd., Panacea Biotec Ltd., and Ennaid Therapeutics, LLC.

Japanese Encephalitis (JE) Therapeutics Pipeline Analysis
By Phase
By Molecule Type
By Route of Administration
By Company